In this issue:
Impact of pembrolizumab on ovarian function in triple-negative breast cancer
Sacituzumab tirumotecan in metastatic triple-negative breast cancer
OS with inavolisib in PIK3CA-mutated advanced breast cancer
Breast tumour-bed biopsy for predicting pathological CR
First-line CDK4/6 inhibitors + endocrine therapy in advanced hormone receptor+, HER2– breast cancer
Adding olanzapine to anthracycline regimens for breast cancer
Trastuzumab deruxtecan outcomes by biomarker status, treatment line and prior sacituzumab govitecan
Patient-reported tolerance of 90 days of preoperative endocrine therapy
Olive oil consumption and breast cancer risk
CDK2/4/6 inhibitor for breast cancer
Please login below to download this issue (PDF)